Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
65.17 (1y: +22%)
Market Cap 30.68 B P/E(ttm) 16.60
Enterprise Value 34.09 B P/B 2.90
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.37
COV's Cash to Debt is ranked lower than
80% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. COV: 0.37 )
COV' s 10-Year Cash to Debt Range
Min: 0.11   Max: 0.49
Current: 0.37
0.11
0.49
Equity to Asset -0.048
COV's Equity to Asset is ranked lower than
699300% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. COV: -0.048 )
COV' s 10-Year Equity to Asset Range
Min: -0.08   Max: 1
Current: -0.05
-0.08
1
Interest Coverage 12.7
COV's Interest Coverage is ranked lower than
71% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 73.90 vs. COV: 12.7 )
COV' s 10-Year Interest Coverage Range
Min: 3   Max: No Debt
Current: 12.7
F-Score: 4
Z-Score: 2.88
M-Score: -2.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.40
COV's Operating margin (%) is ranked higher than
77% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. COV: 20.40 )
COV' s 10-Year Operating margin (%) Range
Min: 4.3   Max: 26.1
Current: 20.4
4.3
26.1
Net-margin (%) 16.1
COV's Net-margin (%) is ranked higher than
71% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. COV: 16.1 )
COV' s 10-Year Net-margin (%) Range
Min: -3.3   Max: 18
Current: 16.1
-3.3
18
ROE (%) 18
COV's ROE (%) is ranked higher than
79% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.30 vs. COV: 18 )
COV' s 10-Year ROE (%) Range
Min: -4.9   Max: 23.5
Current: 18
-4.9
23.5
ROA (%) 8.6
COV's ROA (%) is ranked higher than
60% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. COV: 8.6 )
COV' s 10-Year ROA (%) Range
Min: -1.8   Max: 9.3
Current: 8.6
-1.8
9.3
ROC (Joel Greenblatt) (%) 49.50
COV's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.40 vs. COV: 49.50 )
COV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.7   Max: 52.7
Current: 49.5
9.7
52.7
Revenue Growth (%) 3.6
COV's Revenue Growth (%) is ranked lower than
81% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.60 vs. COV: 3.6 )
COV' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 6.8
Current: 3.6
0
6.8
EBITDA Growth (%) 8.3
COV's EBITDA Growth (%) is ranked lower than
67% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.70 vs. COV: 8.3 )
COV' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 31.3
Current: 8.3
0
31.3
EPS Growth (%) 21.6
COV's EPS Growth (%) is ranked higher than
67% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.30 vs. COV: 21.6 )
COV' s 10-Year EPS Growth (%) Range
Min: 0   Max: 21.6
Current: 21.6
0
21.6
» COV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

COV Guru Trades in Q2 2012

Jean-Marie Eveillard 1,297,817 sh (+44.58%)
Pioneer Investments 3,125,078 sh (+22.33%)
HOTCHKIS & WILEY 1,471,698 sh (+16.42%)
Paul Tudor Jones 56,494 sh (+10.79%)
Mario Gabelli 556,980 sh (+6.03%)
First Pacific Advisors 5,321,000 sh (+2.67%)
Steven Romick 4,780,000 sh (+2.14%)
John Buckingham 94,859 sh (+0.18%)
Donald Yacktman 1,679,075 sh (+0.04%)
John Paulson 1,800,000 sh (unchged)
Vanguard Health Care Fund 2,150,000 sh (unchged)
Bill Nygren 1,985,000 sh (unchged)
Jim Simons Sold Out
David Dreman Sold Out
Ronald Muhlenkamp 375,820 sh (-0.05%)
John Keeley 76,910 sh (-6.1%)
Private Capital 606,899 sh (-6.9%)
Jeremy Grantham 196,900 sh (-10.34%)
Ray Dalio 22,700 sh (-45.17%)
Dodge & Cox 152,928 sh (-59.14%)
Steven Cohen 24,527 sh (-94.35%)
» More
Q3 2012

COV Guru Trades in Q3 2012

Jim Simons 738,100 sh (New)
Jeremy Grantham 337,800 sh (+71.56%)
Pioneer Investments 4,524,656 sh (+44.79%)
Mario Gabelli 567,201 sh (+1.84%)
John Keeley 76,990 sh (+0.1%)
Steven Romick 4,780,000 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Donald Yacktman 1,679,075 sh (unchged)
Bill Nygren 1,985,000 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Vanguard Health Care Fund 2,150,000 sh (unchged)
John Paulson Sold Out
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
First Pacific Advisors 5,319,700 sh (-0.02%)
Ronald Muhlenkamp 374,800 sh (-0.27%)
HOTCHKIS & WILEY 1,466,798 sh (-0.33%)
Jean-Marie Eveillard 1,287,063 sh (-0.83%)
John Buckingham 88,745 sh (-6.45%)
Dodge & Cox 139,253 sh (-8.94%)
Private Capital 545,154 sh (-10.17%)
Steven Cohen 5,415 sh (-77.92%)
» More
Q4 2012

COV Guru Trades in Q4 2012

Bruce Kovner 10,000 sh (New)
Ray Dalio 78,696 sh (New)
Paul Tudor Jones 5,400 sh (New)
Steven Cohen 67,798 sh (+1152.04%)
Jim Simons 1,423,100 sh (+92.81%)
Bill Nygren 2,128,000 sh (+7.2%)
John Keeley 78,560 sh (+2.04%)
Steven Romick 4,851,700 sh (+1.5%)
First Pacific Advisors 5,399,500 sh (+1.5%)
Yacktman Focused Fund 850,000 sh (unchged)
Jeremy Grantham 403,751 sh (unchged)
Yacktman Focused Fund 800,000 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Donald Yacktman 1,679,075 sh (unchged)
John Buckingham 88,707 sh (-0.04%)
Ronald Muhlenkamp 371,640 sh (-0.84%)
Vanguard Health Care Fund 2,100,000 sh (-2.33%)
HOTCHKIS & WILEY 1,376,298 sh (-6.17%)
Pioneer Investments 4,168,985 sh (-7.86%)
Mario Gabelli 519,858 sh (-8.35%)
Private Capital 462,489 sh (-15.16%)
Dodge & Cox 117,978 sh (-15.28%)
Jean-Marie Eveillard 1,014,988 sh (-21.14%)
» More
Q1 2013

COV Guru Trades in Q1 2013

Leon Cooperman 887,300 sh (New)
Paul Tudor Jones 380,400 sh (+6944.44%)
Steven Cohen 195,479 sh (+188.33%)
Jeremy Grantham 511,451 sh (+26.67%)
Vanguard Health Care Fund 2,397,600 sh (+14.17%)
Donald Yacktman 1,801,075 sh (+7.27%)
Mario Gabelli 553,434 sh (+6.46%)
John Keeley 81,060 sh (+3.18%)
Ronald Muhlenkamp 374,540 sh (+0.78%)
John Buckingham 89,040 sh (+0.38%)
Yacktman Focused Fund 800,000 sh (unchged)
Bill Nygren 2,128,000 sh (unchged)
Steven Romick 4,851,700 sh (unchged)
Yacktman Fund 850,000 sh (unchged)
Jim Simons Sold Out
Bruce Kovner Sold Out
Pioneer Investments 4,164,643 sh (-0.1%)
First Pacific Advisors 5,348,800 sh (-0.94%)
Dodge & Cox 115,117 sh (-2.43%)
Private Capital 394,673 sh (-14.66%)
HOTCHKIS & WILEY 1,127,152 sh (-18.1%)
Ray Dalio 60,996 sh (-22.49%)
Jean-Marie Eveillard 700,891 sh (-30.95%)
» More
» Details

Insider Trades

Latest Guru Trades with COV

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2013-03-31 New Buy0.93%$57.74 - $67.84 $ 65.214%887300
Jean-Marie Eveillard 2013-03-31 Reduce -30.95%0.06%$57.74 - $67.84 $ 65.214%700891
Ray Dalio 2013-03-31 Reduce -22.49%0.01%$57.74 - $67.84 $ 65.214%60996
Jean-Marie Eveillard 2012-12-31 Reduce -21.14%0.06%$53.36 - $60.44 $ 65.2114%1014988
Ray Dalio 2012-12-31 New Buy0.05%$53.36 - $60.44 $ 65.2114%78696
John Paulson 2012-09-30 Sold Out 0.8%$50.6 - $59.77 $ 65.2117%0
Ray Dalio 2012-09-30 Sold Out 0.02%$50.6 - $59.77 $ 65.2117%0
Jean-Marie Eveillard 2012-06-30 Add 44.58%0.08%$50.45 - $55.58 $ 65.2122%1297817
David Dreman 2012-06-30 Sold Out 0.07%$50.45 - $55.58 $ 65.2122%0
Ray Dalio 2012-06-30 Reduce -45.17%0.02%$50.45 - $55.58 $ 65.2122%22700
Dodge & Cox 2012-06-30 Reduce -59.14%0.02%$50.45 - $55.58 $ 65.2122%152928
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Covidien PLC

Paulson Says Bet Against Europe to Blame for Down Year, Slashed EU Holdings in Q3
December 6, 2012
John Paulson - Paulson Says Bet Against Europe To Blame For Down Year, Slashed EU Holdings In Q3
Paulson’s pessimistic outlook for the European Union and the euro currency cost him in 2012. The founder of hedge fund Paulson & Co. is attributing this year’s losses, which have placed it among the most underperforming hedge funds, primarily to a wrongway forecast that the situation in Europe would worsen and the euro collapse, and positioning his fund accordingly, according to Bloomberg. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 16.70
COV's P/E(ttm) is ranked higher than
75% of the 107 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.90 vs. COV: 16.70 )
COV' s 10-Year P/E(ttm) Range
Min: 11.06   Max: 28.59
Current: 16.7
11.06
28.59
P/B 2.90
COV's P/B is ranked lower than
60% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. COV: 2.90 )
COV' s 10-Year P/B Range
Min: 1.81   Max: 3.69
Current: 2.9
1.81
3.69
P/S 2.60
COV's P/S is ranked lower than
56% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. COV: 2.60 )
COV' s 10-Year P/S Range
Min: 1.37   Max: 4.25
Current: 2.6
1.37
4.25
PFCF 17.90
COV's PFCF is ranked higher than
72% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.70 vs. COV: 17.90 )
COV' s 10-Year PFCF Range
Min: 9.8   Max: 234.24
Current: 17.9
9.8
234.24
EV-to-EBIT 14.1
COV's EV-to-EBIT is ranked higher than
59% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.73 vs. COV: 14.1 )
COV' s 10-Year EV-to-EBIT Range
Min: 7.4   Max: 97.8
Current: 14.1
7.4
97.8
PEG 1.8
COV's PEG is ranked higher than
53% of the 59 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. COV: 1.8 )
COV' s 10-Year PEG Range
Min: 0.52   Max: 1.85
Current: 1.8
0.52
1.85
Shiller P/E 24.9
COV's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: vs. COV: 24.9 )
COV' s 10-Year Shiller P/E Range
Min: 22.17   Max: 25.7
Current: 24.9
22.17
25.7

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.50
COV's Dividend Yield is ranked higher than
51% of the 72 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.53 vs. COV: 1.50 )
COV' s 10-Year Dividend Yield Range
Min: 0.36   Max: 2.28
Current: 1.5
0.36
2.28
Dividend Payout 0.2609
COV's Dividend Payout is ranked higher than
68% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. COV: 0.2609 )
COV' s 10-Year Dividend Payout Range
Min: 0.16   Max: 0.37
Current: 0.26
0.16
0.37
Dividend growth (3y) 8.1
COV's Dividend growth (3y) is ranked lower than
61% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.30 vs. COV: 8.1 )
COV' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 46.6
Current: 8.1
0
46.6
Yield on cost (5-Year) 2.01
COV's Yield on cost (5-Year) is ranked higher than
74% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.53 vs. COV: 2.01 )
COV' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 3.05
Current: 2.01
0.48
3.05
Share Buyback Rate 1
COV's Share Buyback Rate is ranked higher than
56% of the 32 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. COV: 1 )
COV' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.4
Current: 1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 14.4
COV's Price/Net Current Asset Value is ranked higher than
53% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.00 vs. COV: 14.4 )
COV' s 10-Year Price/Net Current Asset Value Range
Min: 6.4   Max: 13.7
Current: 14.4
6.4
13.7
Price/DCF (Projected) 1.3
COV's Price/DCF (Projected) is ranked higher than
66% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. COV: 1.3 )
COV' s 10-Year Price/DCF (Projected) Range
Min: 1.2   Max: 1.2
Current: 1.3
Price/Median PS Value 1.1
COV's Price/Median PS Value is ranked higher than
51% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. COV: 1.1 )
COV' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 1.9
Current: 1.1
0.8
1.9
Price/Peter Lynch Fair Value 1.8
COV's Price/Peter Lynch Fair Value is ranked lower than
59% of the 32 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. COV: 1.8 )
COV' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 0.6
Current: 1.8
Earnings Yield (Greenblatt) 7.10
COV's Earnings Yield (Greenblatt) is ranked higher than
61% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. COV: 7.10 )
COV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 13.6
Current: 7.1
1
13.6
Forward Rate of Return (Yacktman) 13.03
COV's Forward Rate of Return (Yacktman) is ranked lower than
57% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.37 vs. COV: 13.03 )
COV' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.1   Max: 32.5
Current: 13.03
5.1
32.5

Business Description

Covidien plc formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. The Company operates its business through four segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, soft tissue repair products, energy devices, oximetry and monitoring products, airway and ventilation products, vascular devices, SharpSafety products, clinical care products and other medical device products; Imaging Solutions, which includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products, which includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, which includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products (OEM). The Company's customers include hospitals, surgi-centers, alternate site facilities, including long-term care facilities and imaging centers, drug manufacturers and retailers throughout the world. Its energy devices include its vessel sealing products, electrosurgical products, ablation products and related capital equipment. The Company's oximetry and monitoring products include its sensors and monitors products and its temperature management products. Its airway and ventilation products include its airway products, ventilator products, breathing systems, sleep products and inhalation therapy products. The Company offers a line of products used to monitor, diagnose and treat respiratory disease and sleep disorders. Through its Nellcor brand, the Company established pulse oximetry, which measures oxygen in the blood Imaging Solutions segment develops, manufactures and markets products, such as radiopharmaceuticals, which includes radioactive isotopes and associated pharmaceutical products used for the diagnosis and treatment of disease, and contrast products, which includes contrast delivery systems and contrast agents. The Pharmaceutical Products segment develops, manufactures and distributes the products, such as dosage pharmaceuticals, active pharmaceutical ingredients (API). The Medical Supplies segment develops, manufactures and distributes the products, su
Company Website
Industry: Medical Instruments & Supplies
Compare:WST, BAX, TMO, COO, ISRG
Traded in other countries:6COP.Germany
» More Articles for NYSE:COV

Headlines

Articles On GuruFocus.com
My 4 Favorites from the 20 Most Recommended Dividend Stocks at All-Time Highs Jan 19 2013 
The 3 Most-Recommended Healthcare Stocks Jan 02 2013 
Paulson Says Bet Against Europe to Blame for Down Year, Slashed EU Holdings in Q3 Dec 06 2012 
Donald Yacktman Finds Two Undervalued Companies in His Most Bought, In-Favor Sector of Q3 Dec 04 2012 
GuruFocus.com Interview with Steve Romick, Portfolio Manager of FPA Crescent Oct 09 2012 
The Best Stocks With Dividend Growth From Last Week (September 24 – September 30, 2012) Sep 30 2012 
12 Dividend Challengers With Huge Potential To Become A Dividend Hero Sep 15 2012 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
Q&A with Investor Steven Romick of FPA Funds Aug 28 2012 
Steven Romick's Top Stock Picks Jun 21 2012 

More From Our Partners
St. Jude Begins EnligHTNment Study - Analyst Blog May 24 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial